MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. NUTX
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

Nutex Health (NUTX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Nutex Health
NasdaqCM•Healthcare•Medical Care Facilities
$193.24-4.44(-0.02%)Market closed
Market Cap
$1.43B
P/E
7.7x
P/S
1.7x
P/B
3.6x

Nutex Health Inc. operates as a healthcare services and operations company in the United States. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The Hospital segment develops and operates a network of micro hospitals, specialty hospitals, and hospital outpatient departments that offer healthcare services, including emergency room care, inpatient care, and behavioural health. It also provides imaging services, such as CT scan, X-ray, MRI, ultrasound, etc.; laboratory services; and onsite inpatient pharmacies. The PHM segment provides management, administrative, and other support services to its affiliated hospitals and physician groups by establishing and operating provider networks, such as independent physician associations (IPAs); and a cloud-based technology platform for IPAs. The Real Estate segment owns and leases land and hospital buildings. Nutex Health Inc. was founded in 2011 and is headquartered in Houston, Texas.

A

How this company scores

ExcellentMetricSide Score: 86/100

Strongest: Profitability (25/25); weakest: Growth (18/25).

Profitability25/25
Growth18/25
Balance Sheet & Red Flags19/25
Cash & Earnings Quality24/25
Strengths
Rising free cash flowStrong marginsHigh ROERising earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 7.7x5y range 3.0x – 589.7x
P/E 7.7x · near its 8-quarter median

Currently near its 8-quarter median.

P/S · 1.7x5y range 0.1x – 18637.0x
P/S 1.7x · below its 20-quarter median

Currently below its 20-quarter median.

P/B · 3.6x5y range 0.5x – 3961.4x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 4 quarters — monitor for earnings quality deterioration.

Share Dilution

Red Flag

Shares outstanding increased 34.7% — significant dilution, likely from stock compensation or capital raises.

Price & Volume
Market Cap $1.43B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$846.72M
7%
Q. Revenue
$210.75M
14%
TTM EBITDA
$393.72M
2Q
TTM Op. Income
$372.72M
2Q
Q. Op. Income
$121.72M
2Q
TTM Net Income
$186.50M
2Q
Q. Net Income
$65.84M
2Q
EPS
$9.58
425%
Shares Out.
$6.87M
15%
$846.72M in TTM revenue grew 6.9% YoY, reaching $210.75M last quarter. TTM EBITDA of $393.72M and TTM operating income of $372.72M show growth is flowing through to the bottom line. TTM net income of $186.50M means revenue is converting into profit. Over the past year, TTM revenue is up 7% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin
67.0%
2Q
EBITDA Margin
60.3%
2Q
Op. Margin
57.8%
2Q
Net Margin
31.2%
2Q
Op. margin of 57.8% is up 44.0% YoY — cost efficiency is improving. Net margin at 31.2% and gross margin of 67.0% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
7.7x
49%
P/S Ratio
1.7x
80%
P/B Ratio
3.6x
15%
At 7.7x P/E, the stock trades below typical market levels. P/S of 1.7x and P/B of 3.6x provide additional context. P/E sits below typical market levels while revenue is growing. Over the past year, P/E is down 49% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$964.63M
2Q
Cash
$205.21M
112%
Long-Term Debt
$31.11M
52%
Book Value
$394.32M
7Q
D/E Ratio
0.1
9%
Debt/EBITDA
0.2
2Q
With $964.63M in assets and $31.11M in long-term debt, D/E is 0.1and book value is $394.32M — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is down 9% — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$34.20M
25%
TTM Free Cash Flow
$274.17M
7Q
FCF Margin
32.4%
4Q
FCF / Net Income
1.5
2Q
TTM FCF of $274.17M on $34.20M in operating cash flow. The FCF / Net Income ratio of 1.5x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 7 consecutive quarters — an improving trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General
P/B 3.6x
· below its 20-quarter median

Currently below its 20-quarter median.